Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation

被引:10
|
作者
Habel, Nicole [1 ]
de Lavallaz, Jeanne du Fay [2 ]
Infeld, Margaret [1 ]
Koehler, Jodi L. [3 ]
Ziegler, Paul D. [3 ]
Lustgarten, Daniel L. [1 ]
Meyer, Markus [4 ]
机构
[1] Univ Vermont, Dept Med, Div Cardiol, Larner Coll Med, 111 Colchester Ave, Burlington, VT 05401 USA
[2] Univ Hosp Basel, Dept Med, Basel, Switzerland
[3] Medtronic, Diagnost & Monitoring Res, Mounds View, MN 55112 USA
[4] Univ Minnesota, Lillehei Heart Inst, Dept Med, Coll Med, Minneapolis, MN 55455 USA
来源
INTERNATIONAL JOURNAL OF CARDIOLOGY CARDIOVASCULAR RISK AND PREVENTION | 2023年 / 17卷
关键词
Arrhythmia; Diastolic dysfunction; HFpEF; Insertable cardiac monitor; Natriuretic peptide; END-POINT REDUCTION; BLOOD-PRESSURE; LOSARTAN INTERVENTION; DIASTOLIC DYSFUNCTION; RANDOMIZED-TRIAL; HYPERTENSION; DISEASE; RISK; DETERMINANTS; PERFORMANCE;
D O I
10.1016/j.ijcrp.2023.200182
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Lower heart rates (HRs) prolong diastole, which increases filling pressures and wall stress. As a result, lower HRs may be associated with higher brain natriuretic peptide (BNP) levels and incident atrial fibrillation (AF). Beta-blockers may increase the risk for AF due to suppression of resting HRs.Objective: Examine the relationships of HR, BNP, beta-blockers and new-onset AF in the REVEAL-AF and SPRINT cohort of subjects at risk for developing AF. Methods: In REVEAL-AF, 383 subjects without a history of AF and a mean CHA2DS2VASC score of 4.4 +/- 1.3 received an insertable cardiac monitor and were followed up to 30 months. In SPRINT, 7595 patients without prior history of AF and a mean CHA2DS2VASC score of 2.3 +/- 1.2 were followed up to 60 months. Results: The median daytime HR in the REVEAL-AF cohort was 75bpm [IQR 68-83]. Subjects with below-median HRs had 2.4-fold higher BNP levels compared to subjects with above-median HRs (median BNP [IQR]: 62 pg/dl [37-112] vs. 26 pg/dl [13-53], p < 0.001). HRs <75bpm were associated with a higher incidence of AF: 37% vs. 27%, p < 0.05. This was validated in the SPRINT cohort after adjusting for AF risk factors. Both a HR < 75bpm and beta-blocker use were associated with a higher rate of AF: 1.9 vs 0.7% (p < 0.001) and 2.5% vs. 0.6% (p < 0.001), respectively. The hazard ratio for patients on beta-blockers to develop AF was 3.72 [CI 2.32, 5.96], p < 0.001.Conclusions: Lower HRs are associated with higher BNP levels and incident AF, mimicking the hemodynamic effects of diastolic dysfunction. Suppression of resting HR by beta-blockers could explain their association with incident AF.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry
    Gautier, Alexandre
    Picard, Fabien
    Ducrocq, Gregory
    Elbez, Yedid
    Fox, Kim M.
    Ferrari, Roberto
    Ford, Ian
    Tardif, Jean-Claude
    Tendera, Michal
    Steg, Philippe Gabriel
    EUROPEAN HEART JOURNAL, 2024, 45 (05) : 366 - 375
  • [32] Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study)
    Ko, Darae
    Riles, Eric M.
    Marcos, Ernaldo G.
    Magnani, Jared W.
    Lubitz, Steven A.
    Lin, Honghuang
    Long, Michelle T.
    Schnabel, Renate B.
    McManus, David D.
    Ellinor, Patrick T.
    Ramachandran, Vasan S.
    Wang, Thomas J.
    Gerszten, Robert E.
    Benjamin, Emelia J.
    Yin, Xiaoyan
    Rienstra, Michiel
    AMERICAN JOURNAL OF CARDIOLOGY, 2016, 118 (10) : 1493 - 1496
  • [33] Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study
    Tilly, Martijn J.
    Geurts, Sven
    Donkel, Samantha J.
    Ikram, M. Arfan
    de Groot, Natasja M. S.
    de Maat, Moniek P. M.
    Kavousi, Maryam
    CLINICAL RESEARCH IN CARDIOLOGY, 2022, 111 (01) : 96 - 104
  • [34] Evaluation and care of a patient with new-onset atrial fibrillation
    Moayedi, Yasbanoo
    Abdel-Qadir, Husam M.
    Dorian, Paul
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (03) : 204 - 205
  • [35] The prospective effect of lipoprotein(a) on new-onset atrial fibrillation in patients with chronic heart failure
    Li, Wen-Jia
    Li, Ming-Hong
    Yin, Rui
    Cui, Yu-Qi
    Yin, Lei
    Jiang, Shi-Liang
    Cui, Lian-Qun
    Chen, Li-Ming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (09): : 18316 - 18323
  • [36] Trajectories of Risk Factors and Risk of New-Onset Atrial Fibrillation in the Framingham Heart Study
    Rahman, Faisal
    Yin, Xiaoyan
    Larson, Martin G.
    Ellinor, Patrick T.
    Lubitz, Steven A.
    Vasan, Ramachandran S.
    McManus, David D.
    Magnani, Jared W.
    Benjamin, Emelia J.
    HYPERTENSION, 2016, 68 (03) : 597 - +
  • [37] Amplified P-wave duration predicts new-onset atrial fibrillation in patients with heart failure with preserved ejection fraction
    Björn Müller-Edenborn
    Jan Minners
    Sascha Kocher
    Juan Chen
    Wolfgang Zeh
    Heiko Lehrmann
    Jürgen Allgeier
    Franz-Josef Neumann
    Thomas Arentz
    Amir Jadidi
    Clinical Research in Cardiology, 2020, 109 : 978 - 987
  • [38] Amplified P-wave duration predicts new-onset atrial fibrillation in patients with heart failure with preserved ejection fraction
    Mueller-Edenborn, Bjoern
    Minners, Jan
    Kocher, Sascha
    Chen, Juan
    Zeh, Wolfgang
    Lehrmann, Heiko
    Allgeier, Juergen
    Neumann, Franz-Josef
    Arentz, Thomas
    Jadidi, Amir
    CLINICAL RESEARCH IN CARDIOLOGY, 2020, 109 (08) : 978 - 987
  • [39] Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation
    De Vos, C. B.
    Weijs, B.
    Crijns, H. J. G. M.
    Cheriex, E. C.
    Palmans, A.
    Habets, J.
    Prins, M. H.
    Pisters, R.
    Nieuwlaat, R.
    Tieleman, R. G.
    HEART, 2009, 95 (10) : 835 - 840
  • [40] In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study
    Wachtell, Kristian
    Gerdts, Eva
    Aurigemma, Gerard P.
    Boman, Kurt
    Dahlof, Bjorn
    Nieminen, Markku S.
    Olsen, Michael Hecht
    Okin, Peter M.
    Palmieri, Vittorio
    Rokkedal, Jens E.
    Devereux, Richard B.
    BLOOD PRESSURE, 2010, 19 (03) : 169 - 175